KRAS and neoplasm: In vivo data with pulsatile MEK inhibition in a transplantable KRAS model and in a genetically engineered mouse model bearing human KRASG12C substitution were consistent with the ex vivo observations: the pulsatile treatment had a superior anti-tumor activity and delayed drug resistance in comparison with continuous exposure.